ArticleChildren (Basel, Switzerland)2025
Factors Associated with COVID-19 Infection Related Multisystem Inflammatory Syndrome in Children: A Multicenter Matched Case-Control Study.
Article in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
objectivesAfter pandemic of COVID-19, there were increased the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C), as reported by the Centers for Disease Control and Prevention (CDC). However, it remains unclear which specific factors link MIS-C to COVID-19 following infection. This study aims to investigate the factors associated with MIS-C in children infected with COVID-19.
methodsA multicenter-matched case-control study was conducted across Chum Phae, Khon Kaen, and Srinagarind Hospitals, Thailand. We included patients under 21 years old from those hospitals from January 2021 to February 2024. The cases were patients diagnosed with MIS-C, while the controls had a history of COVID-19 infection but had not been diagnosed with MIS-C at least 3 months post-infection. The matching criteria for cases and controls, in a 1:2 ratio, included gender and age. The association between various factors and MIS-C was examined using conditional logistic regression.
resultsA total of 34 MIS-C cases were matched with 68 controls. We found that antiviral therapy administered during COVID-19 infection was linked to a reduced risk of MIS-C development, with an adjusted odds ratio of 0.06 (95% CI: 0.02-0.20). However, this study found no association between COVID-19 vaccination and nutritional status in the development of MIS-C.
conclusionsThe administration of antiviral treatment during COVID-19 infection was associated with a diminished incidence of MIS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.